Search clinical trials for: Liraglutide 1.8mg

Total 532 results

The First Affiliated Hospital of Xiamen University

Unknown

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (LiraGooD)

Overweight and Obesity | Hyperglycaemia (Diabetic) | Type 2 Diabetes Patients

China
University at Buffalo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Liraglutide in Type 1 Diabetes (1966)

Type 1 Diabetes

United States
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Recruiting

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

Schizophrenia

China
Columbia University

Recruiting

Effects of GH and Lirglutide on AgRP

Healthy | Growth Hormone Deficiency

United States
Woman's
Novo Nordisk A/S

Completed

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS (SAXAPCOS)

Polycystic Ovary Syndrome | Pre Diabetes | Obesity Android

United States
Novo Nordisk A/S

Completed

Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Healthy | Diabetes

Netherlands
Novartis Pharmaceuticals

Completed

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Subacute Cutaneous Lupus Erythematosus

Greece, Germany, Italy
The Affiliated Hospital of Qingdao University

Completed

A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

Therapeutic Equivalency

China
Merck Sharp & Dohme LLC

Completed

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Type 2 Diabetes Mellitus
Sunshine Lake Pharma Co., Ltd.

Completed

A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects

Type 2 Diabetes

China
GemVax & Kael

Recruiting

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Progressive Supranuclear Palsy

Korea, Republic of
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Henrik Gudbergsen

Completed

Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (IM-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Parker Research Institute

Completed

Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

Osteoarthritis, Knee

Denmark
Henrik Gudbergsen

Completed

Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance (BIO-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
Henrik Gudbergsen
Novo Nordisk A/S; Cambridge Weight Plan Limited

Completed

Liraglutide 3 mg for Knee Osteoarthritis (LOSEIT)

Obesity | Osteoarthritis

Denmark
Henrik Gudbergsen

Completed

Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)

Obesity | Osteoarthritis

Denmark
JW Pharmaceutical

Completed

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

Hyperuricemia | Gout

Korea, Republic of
University Medical Centre Ljubljana

Completed

Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

Obesity | Polycystic Ovary Syndrome

Slovenia
Chen Wei Ren, MD

Unknown

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Acute Myocardial Infarction

China
Stanford University

Completed

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Inflammation | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset

United States
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Hungary, France, Australia
University Hospital, Caen

Unknown

THE INFLUENCE OF GRAVITY (ARGuide)

Healthy Volunteers

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Glioblastoma | High Grade Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Novo Nordisk A/S

Completed

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Obesity | Overweight

United States, United Kingdom, Canada, Denmark, Finland, Serbia, Poland, Japan, South Africa, Ireland
Lee's Pharmaceutical Limited

Unknown

A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Ovarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

China
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

In-market Utilisation of Liraglutide Used for Weight Management in Europe

Obesity | Metabolism and Nutrition Disorder

Italy, Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Australia
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Subjects

Healthy | Diabetes

Sweden
Novo Nordisk A/S

Completed

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Sweden
St Vincent's University Hospital, Ireland
University College Dublin; Health Research Board, Ireland

Completed

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Sleep Apnea, Obstructive

Ireland
Novo Nordisk A/S

Completed

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes (ROOTS)

Diabetes Mellitus, Type 2 | Diabetes

Belgium
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Diabetes Mellitus, Type 2 | Diabetes

Australia
Novo Nordisk A/S

Completed

Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Obesity | Metabolism and Nutrition Disorder

Netherlands
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

France
Novo Nordisk A/S

Completed

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Netherlands, France, Slovakia
Novo Nordisk A/S

Completed

A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India (Lead-In)

Diabetes Mellitus, Type 2 | Diabetes

India
Novo Nordisk A/S

Completed

Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

Obesity | Metabolism and Nutrition Disorder

Germany
Novo Nordisk A/S

Completed

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Diabetes Mellitus, Type 2 | Diabetes

Spain, Germany, France, United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Obesity | Metabolism and Nutrition Disorder

France, United States, Turkey, Italy, Australia, New Zealand, Canada, Netherlands
Novo Nordisk A/S

Completed

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Russian Federation, Puerto Rico, United Arab Emirates, Brazil

3

Subscribe